Substance P (Synonyms: Neurokinin P)

Name: Substance P
Brand: MedChemExpress
SKU: HY-P0201
Rating: 5.0 (31 reviews)

Cat. No.: HY-P0201 Purity: 99.52%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Substance P (Neurokinin P) is a CNS-penetrant neuropeptide, acting as a neurotransmitter and as a neuromodulator in the CNS. The endogenous receptor for substance P is neurokinin 1 receptor (NK1-receptor, NK1R).

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

Custom Peptide Synthesis

CAS No. : 33507-63-0

사이즈	재고	수량
1 mg	해외재고보유	Estimated Time of Arrival: December 31
5 mg	해외재고보유	Estimated Time of Arrival: December 31
10 mg	해외재고보유	Estimated Time of Arrival: December 31
25 mg	해외재고보유	Estimated Time of Arrival: December 31
50 mg	해외재고보유	Estimated Time of Arrival: December 31
100 mg	해외재고보유	Estimated Time of Arrival: December 31
200 mg	견적 받기
500 mg	견적 받기

or 대량구매 문의

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 31 publication(s) in Google Scholar

Other Forms of Substance P:

Substance P TFA In-stock
Substance P, FAM-labeled 견적 받기

31 Publications Citing Use of MCE Substance P

Histological Imaging/Staining

In Vivo Efficacy Study

RT-PCR

Cell Imaging/Staining

: Substance P purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2024 Apr 22;20(7):2507-2531. [Abstract]; Substance P (SP, 5 nmol/kg; i.v.; once daily for 6 days) alleviates pathological indexes in DSS-induced colitis mice. Representative images of H&E sections and histological score. Scale bar = 100 μm.

: Substance P purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2024 Apr 22;20(7):2507-2531. [Abstract]; Substance P (SP, 5 nmol/kg; i.v.; once daily for 6 days) alleviates pathological indexes in DSS-induced colitis mice. Photographs of colon length.

: Substance P purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2024 Apr 22;20(7):2507-2531. [Abstract]; Substance P (SP, 5 nmol/kg; i.v.; once daily for 6 days) alleviates pathological indexes in DSS-induced colitis mice. (Images spleen)

: Substance P purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2024 Apr 22;20(7):2507-2531. [Abstract]; RT-qPCR assay of inflammatory cytokines (TNF-α, IL-1β, IL-6 and IL-8) in TNF-α-stimulated Caco-2 cells treated with/without Substance P (SP, 25, 50, and 100 nmol) for 24 h. Data are obtained from three independent experiments, and expressed as the mean ± SEM; n = 5-8.

: Substance P purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2024 Apr 22;20(7):2507-2531. [Abstract]; Representative picture of JC-1 staining in TNF-α-treated Caco-2 cells incubated with Substance P (SP, 100 nmol) for 24 h.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Neurokinin Receptor Isoform Specific Products:

View All Isoforms

NK1R NK2R NK3R

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

Biological Activity
순도&문서
References
고객리뷰

제품 설명

IC₅₀ & Target

NK1R	Human Endogenous Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	IC₅₀	1.4 1 Compound: Substance P	Tested for binding affinity against human wild type NK1 receptor expressed in CHO cells, using [125]SP as radioligand. Tested for binding affinity against human wild type NK1 receptor expressed in CHO cells, using [125]SP as radioligand.	[PMID: 11052787]
IM-9	IC₅₀	0.26 1 Compound: SP	Inhibitory activity against binding of [125I]Bolton-Hunter SP to tachykinin NK-1 receptor in human lymphoma IM9 cells. Inhibitory activity against binding of [125I]Bolton-Hunter SP to tachykinin NK-1 receptor in human lymphoma IM9 cells.	10.1016/0960-894X(95)00582-E
CHO	EC₅₀	0.6 1 Compound: SP	SP-induced [Ca2+] mobilization in CHO cells expressing human Tachykinin receptor 1 SP-induced [Ca2+] mobilization in CHO cells expressing human Tachykinin receptor 1	[PMID: 10794691]
CHO	EC₅₀	0.6 1 Compound: SP	SP-induced [Ca2+] mobilization in CHO cells expressing human Tachykinin receptor 1 SP-induced [Ca2+] mobilization in CHO cells expressing human Tachykinin receptor 1	[PMID: 10794691]
CHO	EC₅₀	1 1 Compound: table 1	Compound was evaluated for the inhibition of IPs hydrolysis on intact CHO cells expressing the human tachykinin NK-1 receptor Compound was evaluated for the inhibition of IPs hydrolysis on intact CHO cells expressing the human tachykinin NK-1 receptor	[PMID: 9871768]
CHO	IC₅₀	1.5 1 Compound: SP	Displacement of [125I]BH-SP from human recombinant NK1 receptor expressed in CHO cells after 90 mins Displacement of [125I]BH-SP from human recombinant NK1 receptor expressed in CHO cells after 90 mins	[PMID: 21421318]
CHO	IC₅₀	1.7 1 Compound: Substance P	Tested for binding affinity against Q165A mutant NK1 receptor expressed in CHO cells, using [125]SP as radioligand Tested for binding affinity against Q165A mutant NK1 receptor expressed in CHO cells, using [125]SP as radioligand	[PMID: 11052787]
HEK293	EC₅₀	0.6 1 Compound: SP	Agonist activity at wild type human NK1 receptor expressed in HEK293 cells assessed as increase in [3H]IP accumulation after 20 mins Agonist activity at wild type human NK1 receptor expressed in HEK293 cells assessed as increase in [3H]IP accumulation after 20 mins	[PMID: 22574973]
CHO	EC₅₀	793 1 Compound: Substance P	Compound was evaluated for concentration-dependent and oscillatory increase in [Ca2+], caused by activation of hNK3 receptors in CHO cells Compound was evaluated for concentration-dependent and oscillatory increase in [Ca2+], caused by activation of hNK3 receptors in CHO cells	[PMID: 9871763]
CHO	EC₅₀	8 1 Compound: table 1	Compound was evaluated for the inhibition of cAMP formation on intact CHO cells expressing the human tachykinin NK-1 receptor Compound was evaluated for the inhibition of cAMP formation on intact CHO cells expressing the human tachykinin NK-1 receptor	[PMID: 9871768]
IM-9	IC₅₀	0.61 1 Compound: Substance P	Antagonist activity for Tachykinin receptor 1 as displacement of [3H]-Substance P in human IM-9 cells Antagonist activity for Tachykinin receptor 1 as displacement of [3H]-Substance P in human IM-9 cells	[PMID: 9871670]
CHO	EC₅₀	793 1 Compound: Substance P	Compound was evaluated for concentration-dependent and oscillatory increase in [Ca2+], caused by activation of hNK3 receptors in CHO cells Compound was evaluated for concentration-dependent and oscillatory increase in [Ca2+], caused by activation of hNK3 receptors in CHO cells	[PMID: 9871763]
CHO	EC₅₀	1 1 Compound: table 1	Compound was evaluated for the inhibition of IPs hydrolysis on intact CHO cells expressing the human tachykinin NK-1 receptor Compound was evaluated for the inhibition of IPs hydrolysis on intact CHO cells expressing the human tachykinin NK-1 receptor	[PMID: 9871768]
HEK293	EC₅₀	0.6 1 Compound: SP	Agonist activity at wild type human NK1 receptor expressed in HEK293 cells assessed as increase in [3H]IP accumulation after 20 mins Agonist activity at wild type human NK1 receptor expressed in HEK293 cells assessed as increase in [3H]IP accumulation after 20 mins	[PMID: 22574973]
CHO	IC₅₀	1.4 1 Compound: Substance P	Tested for binding affinity against human wild type NK1 receptor expressed in CHO cells, using [125]SP as radioligand. Tested for binding affinity against human wild type NK1 receptor expressed in CHO cells, using [125]SP as radioligand.	[PMID: 11052787]
LAD2	EC₅₀	0.68 3 Compound: Substance P	Effect on mast cell degranulation in human LAD2 cells assessed as CCL3 release measured after 2 hrs by Luminex bead based assay Effect on mast cell degranulation in human LAD2 cells assessed as CCL3 release measured after 2 hrs by Luminex bead based assay	[PMID: 34266235]
CHO	IC₅₀	1.4 1 Compound: Substance P	Tested for binding affinity against human wild type NK1 receptor expressed in CHO cells, using [125]SP as radioligand. Tested for binding affinity against human wild type NK1 receptor expressed in CHO cells, using [125]SP as radioligand.	[PMID: 11052787]
CHO	IC₅₀	1.5 1 Compound: SP	Displacement of [125I]BH-SP from human recombinant NK1 receptor expressed in CHO cells after 90 mins Displacement of [125I]BH-SP from human recombinant NK1 receptor expressed in CHO cells after 90 mins	[PMID: 21421318]
CHO	IC₅₀	1.5 1 Compound: SP	Displacement of [125I]BH-SP from human recombinant NK1 receptor expressed in CHO cells after 90 mins Displacement of [125I]BH-SP from human recombinant NK1 receptor expressed in CHO cells after 90 mins	[PMID: 21421318]
CHO	IC₅₀	1.5 1 Compound: SP, substance P	Displacement of [125I]BH-SP to human recombinant NK1 receptor in CHO cells Displacement of [125I]BH-SP to human recombinant NK1 receptor in CHO cells	[PMID: 18554914]
CHO	IC₅₀	1.5 1 Compound: SP, substance P	Displacement of [125I]BH-SP to human recombinant NK1 receptor in CHO cells Displacement of [125I]BH-SP to human recombinant NK1 receptor in CHO cells	[PMID: 18554914]
CHO	IC₅₀	1.7 1 Compound: Substance P	Tested for binding affinity against Q165A mutant NK1 receptor expressed in CHO cells, using [125]SP as radioligand Tested for binding affinity against Q165A mutant NK1 receptor expressed in CHO cells, using [125]SP as radioligand	[PMID: 11052787]
CHO	IC₅₀	1.7 1 Compound: Substance P	Tested for binding affinity against Q165A mutant NK1 receptor expressed in CHO cells, using [125]SP as radioligand Tested for binding affinity against Q165A mutant NK1 receptor expressed in CHO cells, using [125]SP as radioligand	[PMID: 11052787]
CHO	EC₅₀	8 1 Compound: table 1	Compound was evaluated for the inhibition of cAMP formation on intact CHO cells expressing the human tachykinin NK-1 receptor Compound was evaluated for the inhibition of cAMP formation on intact CHO cells expressing the human tachykinin NK-1 receptor	[PMID: 9871768]
CHO	IC₅₀	125 1 Compound: Substance P	Compound was evaluated for its ability to displace [3H]NKB binding in hNK3 receptors expressed in CHO cells Compound was evaluated for its ability to displace [3H]NKB binding in hNK3 receptors expressed in CHO cells	[PMID: 9871763]
LAD2	EC₅₀	0.68 3 Compound: Substance P	Effect on mast cell degranulation in human LAD2 cells assessed as CCL3 release measured after 2 hrs by Luminex bead based assay Effect on mast cell degranulation in human LAD2 cells assessed as CCL3 release measured after 2 hrs by Luminex bead based assay	[PMID: 34266235]
CHO	IC₅₀	125 1 Compound: Substance P	Compound was evaluated for its ability to displace [3H]NKB binding in hNK3 receptors expressed in CHO cells Compound was evaluated for its ability to displace [3H]NKB binding in hNK3 receptors expressed in CHO cells	[PMID: 9871763]
CHO	EC₅₀	793 1 Compound: Substance P	Compound was evaluated for concentration-dependent and oscillatory increase in [Ca2+], caused by activation of hNK3 receptors in CHO cells Compound was evaluated for concentration-dependent and oscillatory increase in [Ca2+], caused by activation of hNK3 receptors in CHO cells	[PMID: 9871763]
HEK293	EC₅₀	0.6 1 Compound: SP	Agonist activity at wild type human NK1 receptor expressed in HEK293 cells assessed as increase in [3H]IP accumulation after 20 mins Agonist activity at wild type human NK1 receptor expressed in HEK293 cells assessed as increase in [3H]IP accumulation after 20 mins	[PMID: 22574973]
IM-9	IC₅₀	0.26 1 Compound: SP	Inhibitory activity against binding of [125I]Bolton-Hunter SP to tachykinin NK-1 receptor in human lymphoma IM9 cells. Inhibitory activity against binding of [125I]Bolton-Hunter SP to tachykinin NK-1 receptor in human lymphoma IM9 cells.	10.1016/0960-894X(95)00582-E
IM-9	IC₅₀	0.61 1 Compound: Substance P	Antagonist activity for Tachykinin receptor 1 as displacement of [3H]-Substance P in human IM-9 cells Antagonist activity for Tachykinin receptor 1 as displacement of [3H]-Substance P in human IM-9 cells	[PMID: 9871670]
LAD2	EC₅₀	0.68 3 Compound: Substance P	Effect on mast cell degranulation in human LAD2 cells assessed as CCL3 release measured after 2 hrs by Luminex bead based assay Effect on mast cell degranulation in human LAD2 cells assessed as CCL3 release measured after 2 hrs by Luminex bead based assay	[PMID: 34266235]

In Vitro

The neuropeptide substance P (SP) that are mediated by the neurokinin 1 receptor (NK1-R) desensitize and resensitize, which may be associated with NK1-R endocytosis and recycling. SP and the NK1-R are internalized into the same clathrin immunoreactive vesicles, and then sorted into different compartments. SP is intact at the cell surface and in early endosomes, but slowly degraded in perinuclear vesicles. SP induces clathrin-dependent internalization of the NK1-R. The SP/NK1-R complex dissociates in acidified endosomes. SP is degraded, whereas the NK1-R recycles to the cell surface. SP induces internalization of the NK1-R both in transfected epithelial cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

분자량

1347.63

화학식

C₆₃H₉₈N₁₈O₁₃S

CAS No.

33507-63-0

Appearance

Solid

Color

White to off-white

Sequence

Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH2

Sequence Shortening

RPKPQQFFGLM-NH2

Structure Classification

Others

Initial Source

Endogenous metabolite

선적

Room temperature in continental US; may vary elsewhere.

보관

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

용액&용해도

In Vitro:

H₂O : ≥ 20 mg/mL (14.84 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.7420 mL	3.7102 mL	7.4204 mL
5 mM	0.1484 mL	0.7420 mL	1.4841 mL
10 mM	0.0742 mL	0.3710 mL	0.7420 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

몰농도 계산기
농도 희석 계산기

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (1.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (1.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (1.86 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

순도&문서

Purity: 99.60%

Select Batch:

Data Sheet (277 KB) SDS (393 KB)

COA (252 KB) LCMS (113 KB)

Handling Instructions (2659 KB)

References

[1]. Grady EF, et al. Delineation of the endocytic pathway of substance P and its seven-transmembrane domain NK1 receptor. Mol Biol Cell. 1995 May;6(5):509-24. [Content Brief]

[2]. Zhang L, et al. MiR-34b/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis. Cell Prolif. 2018 Oct 17:e12527. [Content Brief]

[3]. Chappa AK, et al. Characteristics of substance P transport across the blood-brain barrier. Pharm Res. 2006 Jun;23(6):1201-8. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O	1 mM	0.7420 mL	3.7102 mL	7.4204 mL	18.5511 mL
	5 mM	0.1484 mL	0.7420 mL	1.4841 mL	3.7102 mL
	10 mM	0.0742 mL	0.3710 mL	0.7420 mL	1.8551 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Substance P Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Substance P33507-63-0Neurokinin PNeurokinin ReceptorEndogenous MetaboliteNK receptorTachykinin receptorInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
상품명			Requested Quantity *
고객명 *			호칭
메일주소 *			전화번호 *
Department			회사명 *
City			도
Country or Region *
비고

상품명			Lot #
고객명 *			메일주소 *
전화번호			Department *
회사명 *			Country or Region *
비고

Name
이메일 *

	Sorry, but the email address you supplied was invalid.

Substance P (Synonyms: Neurokinin P)

고객리뷰

Other Forms of Substance P:

Substance P Related Antibodies

31 Publications Citing Use of MCE Substance P

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Neurokinin Receptor Isoform Specific Products:

View All Endogenous Metabolite Isoform Specific Products:

Biological Activity

순도&문서

References

고객리뷰

Substance P Related Antibodies

몰농도 계산기

농도 희석 계산기

Complete Stock Solution Preparation Table

Substance P Related Classifications

Keywords:

최근 본 상품:

고객리뷰

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report